Alvin J. Siteman Cancer Center

Washington University Medical Campus

St. Louis, MO

Sorting 2 by

Accepting patients

QUINTESSENTIAL

A Phase 2, Open-Label, Multicenter Study of BMS-986363, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Learn more
  • CAR T Cell
  • GPRC5D
  • Phase 2

Accepting patients

KarMMa-2

A Phase 2, Multi-Cohort, Copen-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma (KARMMA-2)
Learn more
  • CAR T Cell
  • BCMA
  • High Risk
  • Phase 2
  • Has results